NASDAQ:BRTX BioRestorative Therapies (BRTX) Stock Price, News & Analysis $1.66 +0.06 (+3.75%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.65 -0.01 (-0.36%) As of 05/23/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About BioRestorative Therapies Stock (NASDAQ:BRTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BRTX alerts:Sign Up Key Stats Today's Range$1.59▼$1.6650-Day Range$1.55▼$1.9752-Week Range$1.03▼$2.55Volume14,010 shsAverage Volume540,223 shsMarket Capitalization$12.46 millionP/E RatioN/ADividend YieldN/APrice Target$18.00Consensus RatingBuy Company OverviewBioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.Read More… BioRestorative Therapies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreBRTX MarketRank™: BioRestorative Therapies scored higher than 66% of companies evaluated by MarketBeat, and ranked 329th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBioRestorative Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioRestorative Therapies has received no research coverage in the past 90 days.Read more about BioRestorative Therapies' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioRestorative Therapies are expected to grow in the coming year, from ($1.43) to ($0.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioRestorative Therapies is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioRestorative Therapies is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioRestorative Therapies has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about BioRestorative Therapies' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.18% of the float of BioRestorative Therapies has been sold short.Short Interest Ratio / Days to CoverBioRestorative Therapies has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioRestorative Therapies has recently decreased by 16.77%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioRestorative Therapies does not currently pay a dividend.Dividend GrowthBioRestorative Therapies does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.18% of the float of BioRestorative Therapies has been sold short.Short Interest Ratio / Days to CoverBioRestorative Therapies has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioRestorative Therapies has recently decreased by 16.77%, indicating that investor sentiment is improving significantly. News and Social Media0.7 / 5News Sentiment-0.75 News SentimentBioRestorative Therapies has a news sentiment score of -0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for BioRestorative Therapies this week, compared to 0 articles on an average week. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioRestorative Therapies insiders have not sold or bought any company stock.Percentage Held by Insiders25.50% of the stock of BioRestorative Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.38% of the stock of BioRestorative Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioRestorative Therapies' insider trading history. Receive BRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address BRTX Stock News HeadlinesEquities Analysts Set Expectations for BRTX Q2 EarningsMay 20, 2025 | americanbankingnews.comBioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | finance.yahoo.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.May 24, 2025 | Porter & Company (Ad)BioRestorative Therapies, Inc. (BRTX) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comBioRestorative Therapies, Inc: Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded DataMay 13, 2025 | finanznachrichten.deUncovering Potential: BioRestorative Therapies's Earnings PreviewMay 13, 2025 | benzinga.comPhase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded DataMay 13, 2025 | globenewswire.comBioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025May 8, 2025 | globenewswire.comSee More Headlines BRTX Stock Analysis - Frequently Asked Questions How have BRTX shares performed this year? BioRestorative Therapies' stock was trading at $1.43 on January 1st, 2025. Since then, BRTX shares have increased by 16.1% and is now trading at $1.66. View the best growth stocks for 2025 here. How were BioRestorative Therapies' earnings last quarter? BioRestorative Therapies, Inc. (NASDAQ:BRTX) announced its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by $0.24. The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.38 million. BioRestorative Therapies had a negative trailing twelve-month return on equity of 98.49% and a negative net margin of 2,697.08%. Read the conference call transcript. How do I buy shares of BioRestorative Therapies? Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioRestorative Therapies own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioRestorative Therapies investors own include NVIDIA (NVDA), Micron Technology (MU), PayPal (PYPL), Advanced Micro Devices (AMD), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM) and Broadcom (AVGO). Company Calendar Last Earnings5/14/2025Today5/24/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryHealthcare Current SymbolNASDAQ:BRTX CIK1505497 Webwww.biorestorative.com Phone631-760-8100FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$18.00 Low Stock Price Target$18.00 Potential Upside/Downside+984.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,410,000.00 Net Margins-2,697.08% Pretax Margin-3,619.10% Return on Equity-98.49% Return on Assets-75.23% Debt Debt-to-Equity RatioN/A Current Ratio2.95 Quick Ratio2.95 Sales & Book Value Annual Sales$391,000.00 Price / Sales31.86 Cash FlowN/A Price / Cash FlowN/A Book Value$2.45 per share Price / Book0.68Miscellaneous Outstanding Shares7,505,000Free Float5,155,000Market Cap$12.46 million OptionableNot Optionable Beta77.73 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:BRTX) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredThe “black glass” breakthrough behind AI’s next leapAI is advancing fast… But there’s one problem almost no one’s talking about. Power.True Market Insiders | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioRestorative Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioRestorative Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.